TICKERNERD
Menu
DXCMDXCMHealthcare · Medical Devices

DXCM Stock Forecast: DexCom, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$83
−1.87% on the day

The 29 Wall Street analysts covering DexCom, Inc. hold a median 12-month price target of $95 — +13.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 14 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$32.1B
Ticker Nerd rank
99 / 100
Median analyst target
$95
Analysts covering
29
Revenue$1.3B+13.1% y/y
Operating income$318.3M
Net income$249.1M
Free cash flow$184.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−1.0%
1M
−1.4%
YTD
+25.8%
1Y
+26.1%
From 52W high
−9.6%
From 52W low
+52.2%
$55
$92
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

DXCM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores DexCom, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
99 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
99
Value
93
Quality
92
Volatility
86
Revisions
86
Growth
85
Accruals
77
Momentum
74
Size
7

Issuance (99): The share count has been shrinking and the company is not leaning on new borrowing.

Momentum (74): The shares have been drifting down relative to others.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

DXCM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on DXCM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$50$60$70$80$90$100$110$120Jan 26Apr 26Jul 26Oct 26DXCMHigh $115Median $95Low $79

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says29 analysts
26 Buy3 Hold0 Sell
Low $79Median $95High $115

The green dot is the last close — the median target sits +13.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 9 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Oct 2026BarclaysInitiatesOverweight$115
1 Oct 2026RBC CapitalMaintainsOutperform$90 → $105
18 Sept 2026TD CowenReiteratesBuy$95
18 Sept 2026TD CowenReiteratesBuy—
18 Sept 2026Truist SecuritiesMaintainsBuy$93 → $102
18 Sept 2026Truist SecuritiesMaintainsBuy—
4 Aug 2026Argus ResearchMaintainsBuy—
4 Aug 2026Argus ResearchMaintainsBuy$86 → $96
3 Aug 2026Canaccord GenuityMaintainsBuy—
3 Aug 2026Canaccord GenuityMaintainsBuy$82 → $90
31 July 2026BenchmarkMaintainsBuy—
31 July 2026BenchmarkMaintainsBuy$77 → $82
31 July 2026BTIGMaintainsBuy—
31 July 2026BTIGMaintainsBuy$80 → $90
31 July 2026CitigroupMaintainsBuy$84 → $88
31 July 2026CitigroupMaintainsBuy—
31 July 2026JP MorganMaintainsNeutral$65 → $82
31 July 2026JP MorganMaintainsNeutral—
31 July 2026MizuhoMaintainsOutperform$90 → $95
31 July 2026MizuhoMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. DXCM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

DXCM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, DexCom, Inc. returned +26.1% against +17.5% for the S&P 500, dividends included.

DXCM vs S&P 500, last 12 monthsTotal return, rebased to 100
8090100110120130140Jan 26Apr 26Jul 26Oct 26DXCMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

DXCM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.9%
Analysts raising
23
Analysts cutting
0
Fundamentals

DexCom, Inc. (DXCM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
33.8×

Cheaper than 22% of US stocks

Price / sales
6.5×

Cheaper than 19% of US stocks

Price / book
12.2×

Cheaper than 7% of US stocks

EV / EBITDA
22.5×

Cheaper than 13% of US stocks

Growth & margins
Revenue growth (YoY)
13.1%

Higher than 59% of US stocks

Earnings growth (YoY)
38.5%

Higher than 70% of US stocks

Gross margin
63.4%

Higher than 76% of US stocks

Operating margin
24.3%

Higher than 83% of US stocks

Net margin
20.1%

Higher than 82% of US stocks

Returns & dividend
Return on equity
38.5%

Higher than 91% of US stocks

Return on assets
10.3%

Higher than 92% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

DexCom, Inc. (DXCM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • DexCom, Inc. has a market value of $32.1B and an enterprise value of $31.5B.

  • Revenue in the twelve months to 30 June 2026: $5.0B. The latest quarter grew 13.1% year on year.

  • Net income over the same four quarters: $999.7M, a 20.1% net margin.

  • Diluted earnings per share, trailing twelve months: $2.53.

  • Free cash flow in the twelve months to 30 June 2026: $1.4B.

  • Shares outstanding: 377.4M.

  • Trailing P/E: 33.8×; forward P/E: 27.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • DexCom, Inc. employs 11,000 people — $452K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

DXCM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
DXCMDexCom, Inc.$32.1B
99
GEHCGE Healthcare Technologies, Inc.$31.2B
68
STESTERIS Plc (Ireland)$21.2B
83
EWEdwards Lifesciences Corp.$49.8B
93
ZBHZimmer Biomet Holdings, Inc.$18.2B
91
BSXBoston Scientific Corp.$63.7B
56
PENPenumbra, Inc.$12.6B
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own DexCom, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest DXCM news & analysis

Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin

Business Wire · 14 Oct 2026positive

DexCom said results from its CONNECT randomized controlled trial were published in The New England Journal of Medicine. Adults with Type 2 diabetes not using insulin who used Dexcom G7 had an average A1C reduction of 1.6% from a mean baseline of 8.8%.

Why it matters — The publication reports clinical-trial evidence on Dexcom G7 use in adults with Type 2 diabetes who are not on insulin.

Here's Why You Should Retain DexCom Stock in Your Portfolio for Now

Zacks Investment Research · 13 Oct 2026positive

The item highlights DexCom’s strong margins, the G7 15-day rollout and a promising pipeline as supports for growth, while noting risks from factory ramp-up costs, foreign exchange and input prices.

Why it matters — These factors frame the company’s growth outlook alongside cost and operational pressures that DXCM watchers may monitor.

Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading

Business Wire · 6 Oct 2026positive

Dexcom announced the fifth season of Dexcom U, its NIL program for college athletes with diabetes. The record roster includes 27 athletes—12 new and 15 returning—across 13 sports.

Why it matters — The expanded program and accompanying research on diabetes stigma among young athletes are relevant to DXCM watchers tracking the company’s outreach to people with diabetes.

DXCM Report Highlights CGM Growth Opportunity in Type 2 Diabetes Care

Zacks Investment Research · 2 Oct 2026positive

Zacks Investment Research reports that DexCom sees room to expand continuous glucose monitoring (CGM) adoption in Type 2 diabetes care. The company highlights low awareness, reimbursement hurdles and rising GLP-1 use as factors creating new growth opportunities in this segment.

Why it matters — This matters for DXCM watchers because it points to an untapped growth opportunity in the larger Type 2 diabetes market beyond its current CGM customer base.

FAQ

Frequently asked questions about DXCM stock

What is the DXCM stock price forecast for 2026-2027?

The 29 Wall Street analysts covering DexCom, Inc. have a median 12-month price target of $95, with estimates ranging from $79 to $115. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is DXCM stock a buy right now?

Of the 29 analysts covering DexCom, Inc., 26 rate it a Buy, 3 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks DexCom, Inc. 99 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank DXCM?

As at 14 Oct 2026, DexCom, Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (99 of 100).

Will DXCM stock go up?

No one can know that. What the data says: the median 12-month target from 29 analysts implies +13.8% from the last close, and Ticker Nerd's factor model ranks DexCom, Inc. 99 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the DXCM stock forecast for 2030?

No analyst covering DexCom, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for DXCM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $79 to $115 over the next 12 months.

How has DXCM stock performed over the past year?

DexCom, Inc. returned +26.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does DexCom, Inc. do?

DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health.

What is the latest news on DXCM?

The most recent item we track (Business Wire, 14 Oct 2026): "Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin". DexCom said results from its CONNECT randomized controlled trial were published in The New England Journal of Medicine. Adults with Type 2 diabetes not using insulin who used Dexcom G7 had an average A1C reduction of 1.6% from a mean baseline of 8.8%.

Company

About DexCom, Inc.

DexCom Inc. is a medical device company focused on continuous glucose monitoring systems for diabetes and metabolic health. Dexcom develops wearable biosensors, transmitters, receivers, and software that provide real-time glucose readings, trend data, and alerts to help users and clinicians monitor glucose levels without routine fingerstick testing. Its current product lineup includes Dexcom G7, Dexcom G7 15 Day, Dexcom G6, Dexcom ONE+, Stelo, Dexcom Share, and Dexcom Follow, along with digital tools and remote monitoring features that support daily diabetes management. The company serves people with diabetes, adults with prediabetes and type 2 diabetes who do not use insulin, and healthcare professionals across the United States and international markets. Headquartered in San Diego, California, DexCom plays a significant role in the diabetes care technology market through its focus on connected glucose sensing and data-sharing solutions.

CEO Mr. Jacob Steven Leach · 11,000 employees · United States · https://www.dexcom.com